VCEL · Vericel Corporation
$42.53
-1.02% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
90.5
Forward P/E
50.3
Dividend yield
0.0%
Beta
1.02
Avg volume
1M
Employees
0K
Daily Change %
-1.02%
5 Days Change
7.08%
10 Days Change
6.63%
30 Days Change
10.78%
60 Days Change
1.58%
Month to Day Change
8.95%
Year to Day Change
19.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VCEL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-14
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Truist Securities | Maintains | Buy | $58.00 → $52.00 |
| 2026-07-31 | TD Cowen | Maintains | Buy | $55.00 → $58.00 |
| 2026-07-31 | Truist Securities | Reiterates | Buy | $54.00 → $58.00 |
| 2026-07-31 | HC Wainwright & Co. | Maintains | Buy | $70.00 → $72.00 |
| 2026-07-28 | HC Wainwright & Co. | Reiterates | Buy | $70.00 |
| 2026-07-16 | Truist Securities | Maintains | Buy | $42.00 → $54.00 |
| 2026-05-08 | HC Wainwright & Co. | Maintains | Buy | $64.00 |
| 2026-04-15 | Truist Securities | Maintains | Buy | $48.00 → $42.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 4.4% above the 50-day MA ($40.72).
- bullish: Price vs 200-day MA: Trading 10.3% above the 200-day MA ($38.55).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.30) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($29.34) and high ($48.31).
VCEL Price Chart
Loading chart for VCEL…
Fundamentals
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.